BR112023002668A2 - Composições e métodos para tratar cânceres egfr positivos - Google Patents

Composições e métodos para tratar cânceres egfr positivos

Info

Publication number
BR112023002668A2
BR112023002668A2 BR112023002668A BR112023002668A BR112023002668A2 BR 112023002668 A2 BR112023002668 A2 BR 112023002668A2 BR 112023002668 A BR112023002668 A BR 112023002668A BR 112023002668 A BR112023002668 A BR 112023002668A BR 112023002668 A2 BR112023002668 A2 BR 112023002668A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
positive cancer
egfr positive
treat egfr
Prior art date
Application number
BR112023002668A
Other languages
English (en)
Inventor
Oh Julyun
Xu Han
Alexander Kamb Carl
Original Assignee
A2 Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics Inc filed Critical A2 Biotherapeutics Inc
Publication of BR112023002668A2 publication Critical patent/BR112023002668A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA TRATAR CÂNCERES EGFR POSITIVOS. A divulgação fornece células imunes compreendendo um primeiro receptor ativador e um segundo receptor inibidor e métodos para produzir e usar os mesmos para o tratamento de câncer.
BR112023002668A 2020-08-20 2021-08-19 Composições e métodos para tratar cânceres egfr positivos BR112023002668A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063068249P 2020-08-20 2020-08-20
US202063105639P 2020-10-26 2020-10-26
US202163230632P 2021-08-06 2021-08-06
PCT/US2021/046733 WO2022040444A1 (en) 2020-08-20 2021-08-19 Compositions and methods for treating egfr positive cancers

Publications (1)

Publication Number Publication Date
BR112023002668A2 true BR112023002668A2 (pt) 2023-05-02

Family

ID=77711489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002668A BR112023002668A2 (pt) 2020-08-20 2021-08-19 Composições e métodos para tratar cânceres egfr positivos

Country Status (21)

Country Link
US (2) US11602544B2 (pt)
EP (2) EP4442815A2 (pt)
JP (1) JP2023538116A (pt)
KR (1) KR20230052289A (pt)
AU (1) AU2021328478A1 (pt)
BR (1) BR112023002668A2 (pt)
CA (1) CA3189510A1 (pt)
DK (1) DK4058474T3 (pt)
ES (1) ES2984902T3 (pt)
FI (1) FI4058474T3 (pt)
HR (1) HRP20240903T1 (pt)
HU (1) HUE067417T2 (pt)
IL (1) IL300629A (pt)
LT (1) LT4058474T (pt)
MX (1) MX2023002104A (pt)
PL (1) PL4058474T3 (pt)
PT (1) PT4058474T (pt)
RS (1) RS65802B1 (pt)
SI (1) SI4058474T1 (pt)
TW (1) TW202214846A (pt)
WO (1) WO2022040444A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538116A (ja) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド Ｅｇｆｒ陽性がんを治療するための組成物及び方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
DE60130435T2 (de) 2000-02-24 2009-07-23 Invitrogen Corp., Carlsbad Gleichzeitige stimulation und konzentration von zellen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
EP1742958B1 (en) 2004-03-15 2017-05-17 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US7754482B2 (en) 2004-05-27 2010-07-13 The Trustees Of The University Of Pennsylvania Artificial antigen presenting cells and uses therefor
JP2015513399A (ja) 2012-02-22 2015-05-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌の治療のために有用なｔ細胞の存続的集団を作製するための組成物および方法
MA37663B1 (fr) 2012-05-25 2019-12-31 Univ California Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn
BR112015013786B1 (pt) 2012-12-12 2022-03-15 President And Fellows Of Harvard College Sistemas de componente crispr-cas, métodos e composições para manipulação de sequência
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
IL300461A (en) 2012-12-12 2023-04-01 Harvard College Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
BR112015023679A2 (pt) 2013-03-15 2017-10-24 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
DK3071223T3 (da) 2013-11-21 2021-03-29 Autolus Ltd Cell
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
KR102228828B1 (ko) * 2014-03-11 2021-03-16 셀렉티스 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법
US11072644B2 (en) 2014-11-12 2021-07-27 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
WO2016097231A2 (en) 2014-12-17 2016-06-23 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN108064283B (zh) 2015-02-24 2024-01-09 加利福尼亚大学董事会 结合触发的转录开关及其使用方法
EP3268388A1 (en) 2015-03-11 2018-01-17 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
CN107533051B (zh) 2015-03-27 2020-11-13 南加利福尼亚大学 Hla-g作为car t细胞免疫疗法的新靶标
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
KR20180075689A (ko) 2015-11-23 2018-07-04 트르스티스 오브 보스톤 유니버시티 키메라 항원 수용체에 관한 방법 및 조성물
US20190255186A1 (en) 2015-12-02 2019-08-22 Innovative Targeting Solutions Inc. Single variable domain t-cell receptors
KR102386029B1 (ko) 2016-03-11 2022-04-13 2세븐티 바이오, 인코포레이티드 게놈 편집 면역 효과기 세포
AU2017286835B2 (en) 2016-06-29 2023-12-14 Crispr Therapeutics Ag Compositions and methods for gene editing
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
EP4282978A3 (en) 2016-09-28 2023-12-06 Gavish-Galilee Bio Applications Ltd. A universal platform for car therapy targeting a novel antigenic signature of cancer
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018148454A1 (en) 2017-02-09 2018-08-16 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
GB201707783D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
JP7132249B2 (ja) 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体（ｃａｒ）を含む細胞
EP3684821A4 (en) 2017-09-19 2021-06-16 The University Of British Columbia ANTI-HLA-A2 ANTIBODIES AND METHOD OF USING THEREOF
PT3688155T (pt) * 2017-09-28 2023-04-11 Gavish Galilee Bio Appl Ltd Uma plataforma universal para preparar um recetor de antígeno quimérico inibidor (icar)
WO2019090215A2 (en) 2017-11-06 2019-05-09 Monticello Daniel J Dominant negative ligand chimeric antigen receptor systems
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
KR20210088559A (ko) 2018-09-28 2021-07-14 임팩트-바이오 리미티드. 암 요법에 사용하기 위한 활성화 항원 수용체 (aCAR)/저해성 키메라 항원 수용체 (iCAR) 쌍의 식별 방법
CN113164576A (zh) 2018-10-05 2021-07-23 圣安娜儿童癌症研究中心 嵌合抗原受体(car)组
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
KR20220053587A (ko) * 2019-08-09 2022-04-29 에이투 바이오쎄라퓨틱스, 인크. 이형접합성 소실에 반응성인 세포 표면 수용체
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
WO2021030153A2 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
JP2022546315A (ja) 2019-08-20 2022-11-04 センティ バイオサイエンシズ インコーポレイテッド キメラ抑制性受容体
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
US20230029341A1 (en) 2019-12-11 2023-01-26 A2 Biotherapeutics, Inc. Nucleic acid encoding lilrb1-based chimeric antigen receptor
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
JP2023538116A (ja) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド Ｅｇｆｒ陽性がんを治療するための組成物及び方法

Also Published As

Publication number Publication date
US11602544B2 (en) 2023-03-14
AU2021328478A1 (en) 2023-04-20
HUE067417T2 (hu) 2024-10-28
LT4058474T (lt) 2024-08-26
EP4442815A2 (en) 2024-10-09
EP4058474A1 (en) 2022-09-21
HRP20240903T1 (hr) 2024-10-11
FI4058474T3 (fi) 2024-07-01
TW202214846A (zh) 2022-04-16
MX2023002104A (es) 2023-07-10
JP2023538116A (ja) 2023-09-06
US20230277593A1 (en) 2023-09-07
WO2022040444A1 (en) 2022-02-24
SI4058474T1 (sl) 2024-09-30
CA3189510A1 (en) 2022-02-24
PT4058474T (pt) 2024-07-09
EP4058474B1 (en) 2024-05-08
KR20230052289A (ko) 2023-04-19
ES2984902T3 (es) 2024-10-31
DK4058474T3 (da) 2024-07-22
PL4058474T3 (pl) 2024-09-23
RS65802B1 (sr) 2024-08-30
IL300629A (en) 2023-04-01
US20220273721A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
EA201991071A1 (ru) Композиции и способы для лечения ezh2-опосредованного рака
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
GT201200318A (es) Anticuerpos hacia gdf8 humano
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
EA201790332A1 (ru) Дополнительная терапия 25-гидроксивитамином d
EA202091360A1 (ru) Гуманизированные анти-liv1 антитела для лечения рака молочной железы
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
CO2020014599A2 (es) Métodos para tratar cáncer
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
BR112023002668A2 (pt) Composições e métodos para tratar cânceres egfr positivos
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
EA202190862A1 (ru) Способы лечения